zoledronic acid has been researched along with Bone Diseases in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.20) | 18.2507 |
| 2000's | 20 (24.10) | 29.6817 |
| 2010's | 55 (66.27) | 24.3611 |
| 2020's | 7 (8.43) | 2.80 |
| Authors | Studies |
|---|---|
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Abe, M; Harada, T; Hiasa, M; Miki, H; Nakamura, S; Teramachi, J | 1 |
| Marmolejo, D; Mirallas, O; Valdivia, A; Vieito, M | 1 |
| Choupani, J; Gharibi, T; Hagh, MF; Hassanzadeh, A; Marofi, F; Solali, S; Vahedi, G | 1 |
| Kaklamanos, EG; Papadopoulos, MA; Yavropoulou, MP; Zymperdikas, VF | 1 |
| Jayaram, R; O'Donnell, PW; Puleo, DA | 1 |
| James, S; Lee, SL; Lim, A; Simm, PJ; Zacharin, M | 1 |
| Brezina, T; Cristino, J; Finek, J; Giannopoulou, C; Jandova, P; Kolek, M; Lothgren, M; Pásztor, B; Qian, Y | 1 |
| Raje, NS; Yee, AJ | 1 |
| Djulbegovic, B; Kumar, A; Mhaskar, R; Miladinovic, B | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| García-Sanz, R; Hechmati, G; Intorcia, M; Kennedy, L; Raje, N; Roodman, GD; Sabatelli, L; Shimizu, K; Terpos, E; Willenbacher, W | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kanellias, N; Terpos, E | 1 |
| Bolzoni, M; Ferretti, M; Giuliani, N; Palumbo, C; Toscani, D | 1 |
| Accordino, MK; Bhutani, D; Chen, Y; Hershman, DL; Hillyer, GC; Leng, S; Lentzsch, S; Lim, E; Neugut, AI; Tsai, WY; Wright, JD | 1 |
| Brini, AT; Farronato, D; Farronato, G; Giannasi, C; Lombardi, G; Manfredi, B; Niada, S | 1 |
| Ito, E; Kobayashi, A; Kudo, K; Tanaka, T; Terui, K | 1 |
| Bhowmik, D; Campioni, M; Christodoulopoulou, A; Jamotte, A; Kennedy, L; Terpos, E; Willenbacher, W | 1 |
| Allen, MR; Berman, A; Powell, KM; Pulliam, A; Skaggs, C; Wallace, JM | 1 |
| Dimopoulos, MA; Kleber, M; Ntanasis-Stathopoulos, I; Terpos, E | 1 |
| Bismarck, E; Dörsam, J; Ebert, T; Schmitz-Dräger, BJ; Weiss, C | 1 |
| Fujimura, T; Homma, Y; Kume, H; Taguchi, S | 1 |
| Cavo, M; Dimopoulos, MA; Drake, MT; Durie, BG; García-Sanz, R; Jurczyszyn, A; Leleu, X; Lentzsch, S; Merlini, G; Morgan, G; Munshi, N; Raje, N; Rajkumar, SV; Reiman, T; Roodman, GD; Sezer, O; Shimizu, K; Spencer, A; Terpos, E; Turesson, I | 1 |
| Allen, MR; Chen, NX; Gattone, VH; Moe, SM | 1 |
| Alegre, A; Bailén, A; Giraldo, P; Gironella, M | 1 |
| Gamie, Z; Kenanidis, E; Kostakos, T; Kyrkos, J; Papamerkouriou, YM; Papavasiliou, K; Potoupnis, M; Sarris, I; Tsiridis, E | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H | 1 |
| Chantry, AD; Evans, HR; Harris, W; Lawson, MA; Paton-Hough, JM; Ratnabalan, D; Snowden, JA; Walker, RE | 1 |
| Abellá, E; Bargay, J; Blanchard, MJ; de la Rubia, J; García-Sanz, R; Gironella, M; Granell, M; Hernández, MT; Mateos, MV; Moreno, MJ; Ocio, EM; Oriol, A; Palomera, L; Payer, AR; Ribas, P; Ribera, JM; San Miguel, JF; Teruel, AI | 1 |
| George, S; Hummel, K; Kaplan, P; Levine, MA; Monk, HM; Weber, DR | 1 |
| Dalle Carbonare, L; De Franceschi, L; Matte', A; Mori, A; Perbellini, L; Schweiger, V; Siciliano, A; Valenti, MT; Zampieri, G | 1 |
| Abe, M; Miki, H; Nakamura, S | 1 |
| Kajizono, M; Kitamura, Y; Matsuoka, J; Sada, H; Sendo, T; Soga, Y; Sugiura, Y | 1 |
| Anderson, KC; Argonza-Aviles, E; Badros, A; Ericson, SG; Hadala, JT; Montgomery, CW; Munshi, N; Orlowski, R; Raje, N; Vescio, R; Warsi, G | 1 |
| Balakumaran, A; Braun, A; Brown, JE; Fizazi, K; Henry, DH; Lipton, A; Martin, M; Richardson, GE; Saad, F; Shore, N; Smith, MR; Stopeck, AT; Vadhan-Raj, S; Yardley, DA; Zhou, K | 1 |
| Ea, HK; Paycha, F; Poiroux, L; Polivka, M | 1 |
| Fu, R; Gao, S; Jiang, F; Li, L; Liu, H; Liu, Z; Peng, F; Ruan, E; Shao, Z; Song, J; Wang, G | 1 |
| Abdi, E; Chern, B; Copeman, MC; Cosolo, W; Khalafallah, AA; Slancar, M; Woodfield, RJ | 1 |
| Andriani, A; Balleari, E; Boccadoro, M; Bongarzoni, V; Bringhen, S; Caravita, T; D'Arena, G; Guglielmelli, T; Musto, P; Palumbo, A; Petrucci, MT; Pietrantuono, G | 1 |
| Bodingbauer, M; Haas, M; Kainz, A; Klaushofer, K; Misof, BM; Mühlbacher, F; Oberbauer, R; Pakrah, B; Roschger, P; Wekerle, T | 1 |
| Batuman, O; Berenson, JR; Boccia, RV; Duvivier, H; Flam, M; Moezi, MM; Nassir, Y; Swift, RA; Wong, SF; Woytowitz, D; Yellin, O | 1 |
| Haus, U; Jung, K; Lein, M; May, C; Miller, K; Schmidt, K; Schrader, M; Weissbach, L; Wirth, M | 1 |
| Ando, R; Fukami, K; Hashiguchi, M; Hazama, T; Koike, K; Morishige, S; Nagano, M; Nishida, H; Okuda, S; Taguchi, K; Tamaki, K; Ueda, S; Yoshimura, J | 1 |
| Berenson, J; Coleman, RE; Cook, RJ; Lipton, A; Terpos, E | 1 |
| Berenson, JR | 2 |
| Chan, J; Hui, RL; Schottinger, JE; Spence, MM | 1 |
| Body, JJ; Braun, A; Dansey, R; de Boer, RH; Fan, M; Fujiwara, Y; Jiang, Q; Jun, S; Lichinitser, M; Lipton, A; Steger, GG; Stopeck, AT; Tonkin, K; Viniegra, M; Yardley, DA | 1 |
| Guo, A; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR | 1 |
| Brown, J; Burkinshaw, R; Coleman, R; Lester, J; Neville-Webbe, H; Winter, M; Woodward, E | 1 |
| Pozzi, S; Raje, N | 1 |
| Ludwig, H; Zojer, N | 1 |
| Drabick, J; Harvey, H; Lipton, A; Sivendran, S | 1 |
| D'Alessio, A; Daniele, G; De Luca, A; Gallo, M; Giordano, P; Lamura, L; Maiello, MR; Normanno, N; Pergameno, M; Perrone, F | 1 |
| Bensimon, AG; Ericson, SG; Guo, A; Marynchenko, M; Namjoshi, M; Raje, N; Wu, EQ; Yu, AP | 1 |
| Lipton, A | 2 |
| De Stefano, V; Logroscino, CA; Proietti, L; Scaramuzzo, L; Tamburrelli, FC | 1 |
| Ashcroft, AJ; Bell, SE; Child, JA; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Szubert, AJ | 1 |
| Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 1 |
| Morgan, G | 1 |
| Henk, H; Kaura, S; Teitelbaum, A | 1 |
| Dranitsaris, G; Hatzimichael, E | 1 |
| Clark, OA; Djulbegovic, B; Glasmacher, A; Kumar, A; Mhaskar, R; Miladinovic, B; Redzepovic, J; Wheatley, K | 1 |
| Arens, AM; Bell, RJ; Galuppo, LD; Katzman, SA; MacDonald, MH; Maher, O; Nieto, JE; Puchalski, SM; Snyder, JR | 1 |
| Bishr, M; Saad, F | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M | 1 |
| Theriault, RL | 1 |
| Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Bukowski, RM; Colombo-Berra, A; Lipton, A; Rosen, L; Urbanowitz, G; Zheng, M | 1 |
| Dunleavy, R; Liauw, W; Lih, A; Links, M; Segelov, E; Ward, R | 1 |
| Green, JR | 1 |
| Smith, MR | 1 |
| Conti, G | 1 |
| Avcu, F; Ural, AU | 1 |
| Briody, J; Cowell, CT; Högler, W; Hong, J; Little, DG; McQuade, M; Munns, CF; Rajab, MH | 1 |
| Brown, J; Coleman, R; Cook, RJ; Hei, YJ; Lipton, A; Major, P; Saad, F; Smith, MR | 1 |
| Coleman, RE | 1 |
| Andriani, A; Barbarano, L; Bibas, M; Cafro, AM; D'Avanzo, G; Gaglioti, D; Morra, E; Nichelatti, M; Nosari, AM; Riva, F; Taroni, A | 1 |
| Burckhardt, P; Green, JR; Ibarra de Palacios, P; Kandra, A; Leuenberger, P; Sauty, A; Sitzler, L; Thiébaud, D; Zieschang, J | 1 |
31 review(s) available for zoledronic acid and Bone Diseases
| Article | Year |
|---|---|
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.
Topics: Bone and Bones; Bone Diseases; Cytokines; Humans; Multiple Myeloma; Tumor Microenvironment; Zoledronic Acid | 2023 |
Bisphosphonates as Supplement to Dental Treatment: A Network Meta-Analysis.
Topics: Bone Diseases; Diphosphonates; Humans; Network Meta-Analysis; Periodontal Diseases; Zoledronic Acid | 2021 |
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Osteoclasts; RANK Ligand; Treatment Outcome; Zoledronic Acid | 2018 |
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2017 |
Management of multiple myeloma bone disease: impact of treatment on renal function.
Topics: Bone Density Conservation Agents; Bone Diseases; Disease Management; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid | 2018 |
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Diseases; Bone Morphogenetic Proteins; Bortezomib; Genetic Markers; Humans; Mice; Multiple Myeloma; Osteocytes; Osteogenesis; Osteolysis; Zoledronic Acid | 2018 |
Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Diseases; Denosumab; Humans; Multiple Myeloma; RANK Ligand; Zoledronic Acid | 2019 |
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2014 |
Treatment of multiple myeloma bone disease: experimental and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Quality of Life; Zoledronic Acid | 2015 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2015 |
Therapeutic options in the management of myeloma bone disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2010 |
Zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Fractures, Bone; Humans; Imidazoles; Zoledronic Acid | 2011 |
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid | 2011 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid | 2011 |
Pharmacokinetic evaluation of zoledronic acid.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Drug Evaluation; Female; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2011 |
Zoledronic acid: multiplicity of use across the cancer continuum.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Zoledronic Acid | 2011 |
Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Carcinoma, Renal Cell; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Europe; Health Care Costs; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Drug Delivery Systems; Endpoint Determination; Female; Humans; Imidazoles; Male; Neoplasms; Numbers Needed To Treat; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2012 |
Bisphosphonates in multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2012 |
Preventing bone complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Life Style; Male; Prostatic Neoplasms; Selective Estrogen Receptor Modulators; Zoledronic Acid | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Zoledronic acid (Zometa) use in bone disease.
Topics: Bone Diseases; Diphosphonates; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2003 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Bone Density; Bone Diseases; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Osteolysis; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid | 2005 |
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
Topics: Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Humans; Imidazoles; Neoplasms; Zoledronic Acid | 2005 |
[Zoledronic acid in the treatment of prostate cancer].
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Emerging strategies in bone health management for the adjuvant patient.
Topics: Angiogenesis Inhibitors; Animals; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Zoledronic Acid | 2007 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2001 |
18 trial(s) available for zoledronic acid and Bone Diseases
| Article | Year |
|---|---|
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Topics: Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Cost-Benefit Analysis; Czech Republic; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Markov Chains; Models, Econometric; Neoplasms; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Zoledronic Acid | 2017 |
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Cost of Illness; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Health Expenditures; Humans; Imidazoles; Male; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; United States; Zoledronic Acid | 2018 |
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
Topics: Adult; Aged; Bone Diseases; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Survival Rate; Zoledronic Acid | 2015 |
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Peptides; Zoledronic Acid | 2016 |
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Topics: Administration, Cutaneous; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Treatment Outcome; Zoledronic Acid | 2016 |
Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Neoplasms; Prospective Studies; Zoledronic Acid | 2018 |
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Zoledronic Acid | 2008 |
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Osteonecrosis; Radiography; Time Factors; X-Rays; Zoledronic Acid | 2008 |
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Collagen Type I; Diphosphonates; Humans; Imidazoles; Male; Multivariate Analysis; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Zoledronic Acid | 2009 |
Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Humans; Imidazoles; Male; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Risk; Treatment Outcome; Zoledronic Acid | 2010 |
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; RANK Ligand; Zoledronic Acid | 2010 |
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Thalidomide; Zoledronic Acid | 2012 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2003 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
Acute phase response and mineral status following low dose intravenous zoledronic acid in children.
Topics: Acute-Phase Reaction; Adolescent; Bone Density Conservation Agents; Bone Diseases; C-Reactive Protein; Calcium; Child; Child, Preschool; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Male; Parathyroid Hormone; Phosphates; Zoledronic Acid | 2007 |
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Castration; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid | 2007 |
An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.
Topics: Acute-Phase Reaction; Adult; Bone Diseases; Carrier Proteins; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Interleukin-1; Interleukin-6; Leukocyte Count; Male; Middle Aged; Pamidronate; Tumor Necrosis Factor-alpha; Zoledronic Acid | 1997 |
35 other study(ies) available for zoledronic acid and Bone Diseases
| Article | Year |
|---|---|
Grade I meningioma with disseminated bone disease: a rare clinical phenomenon.
Topics: Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Disease Progression; Drug Therapy, Combination; Estrogen Antagonists; Fatal Outcome; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Grading; Octreotide; Pelvic Pain; Pelvis; Radiotherapy; Tamoxifen; Tomography, X-Ray Computed; Zoledronic Acid | 2020 |
ATF4, DLX3, FRA1, MSX2, C/EBP-ζ, and C/EBP-α Shape the Molecular Basis of Therapeutic Effects of Zoledronic Acid in Bone Disorders.
Topics: Bone Diseases; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mesenchymal Stem Cells; Molecular Structure; Osteogenesis; RNA, Messenger; Structure-Activity Relationship; Transcription Factors; Zoledronic Acid | 2020 |
Systems for local, sustained release of zoledronic acid as a potential treatment for metastatic bone disease.
Topics: Bone and Bones; Bone Diseases; Delayed-Action Preparations; Humans; Neoplasms; Zoledronic Acid | 2021 |
Outcomes of Zoledronic Acid Use in Paediatric Conditions.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Zoledronic Acid | 2020 |
Denosumab for myeloma bone disease: ready for prime time?
Topics: Bone Diseases; Denosumab; Double-Blind Method; Humans; Multiple Myeloma; Zoledronic Acid | 2018 |
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Medicare; Multiple Myeloma; Pamidronate; Practice Guidelines as Topic; Retrospective Studies; SEER Program; Treatment Outcome; United States; Zoledronic Acid | 2019 |
Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Calcification, Physiologic; Cell Differentiation; Cell Survival; Cells, Cultured; Collagen Type I; Cytokines; Humans; Osteoblasts; Osteopontin; Zoledronic Acid | 2019 |
Zoledronic acid for relapsed Langerhans cell histiocytosis with isolated skull bone lesion.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Diseases; Child; Female; Histiocytosis, Langerhans-Cell; Humans; Magnetic Resonance Imaging; Recurrence; Skull; Zoledronic Acid | 2019 |
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
Topics: Bone Density Conservation Agents; Bone Diseases; Cost-Benefit Analysis; Denosumab; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Health Expenditures; Humans; Markov Chains; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; Zoledronic Acid | 2019 |
Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.
Topics: Animals; Biomechanical Phenomena; Bone Diseases; Calcification, Physiologic; Cancellous Bone; Diaphyses; Drug Therapy, Combination; Femur; Fractures, Bone; Male; Mice, Inbred C57BL; Raloxifene Hydrochloride; Zoledronic Acid | 2019 |
Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Life Expectancy; Male; Numbers Needed To Treat; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Time Factors; Treatment Outcome; Zoledronic Acid | 2013 |
Zoledronic acid administration in aggressive castration- resistant prostate cancer.
Topics: Aged; Bone and Bones; Bone Diseases; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2012 |
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Humans; Imidazoles; International Cooperation; Magnetic Resonance Imaging; Medical Oncology; Multiple Myeloma; Osteonecrosis; Outcome Assessment, Health Care; Pamidronate; Positron-Emission Tomography; Practice Guidelines as Topic; Radiotherapy; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.
Topics: Animals; Bone Diseases; C-Reactive Protein; Calcium; Dental Cementum; Dental Enamel; Diphosphonates; Disease Models, Animal; Heterozygote; Imidazoles; Inflammation; Kidney Diseases; Male; Mandible; Parathyroid Hormone; Periodontitis; Phenotype; Rats; Tomography, X-Ray Computed; X-Ray Microtomography; Zoledronic Acid | 2013 |
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Diseases; Bone Marrow; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multiple Myeloma; Neoplasm Transplantation; Oligopeptides; Tumor Cells, Cultured; Zoledronic Acid | 2015 |
Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
Topics: Acute-Phase Reaction; Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Diseases; Calcitriol; Calcium; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Osteoporosis; Prospective Studies; Retrospective Studies; Risk Factors; Young Adult; Zoledronic Acid | 2015 |
Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease.
Topics: Anemia, Sickle Cell; Animals; Bone Diseases; Cathepsin K; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Interleukin-6; Mice; Mice, Transgenic; Osteoclasts; Osteonectin; RANK Ligand; Reperfusion Injury; Zoledronic Acid | 2015 |
[Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2015 |
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Topics: Aged; Anemia; Bone Density Conservation Agents; Bone Diseases; Denosumab; Dental Care; Diabetes Complications; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2015 |
Efficacy of zoledronic acid in Erdheim-Chester disease: A case report.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Erdheim-Chester Disease; Female; Follow-Up Studies; Humans; Imidazoles; Zoledronic Acid | 2016 |
CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
Topics: Adult; Aged; Animals; Bone Diseases; Bone Marrow Cells; Bone Remodeling; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cysteine-Rich Protein 61; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mice; Middle Aged; Multiple Myeloma; Neoplasm Transplantation; Osteoblasts; Wnt Signaling Pathway; Zoledronic Acid | 2017 |
Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation.
Topics: Adult; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases; Calcification, Physiologic; Diphosphonates; Female; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Zoledronic Acid | 2008 |
[Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma].
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Dexamethasone; Diphosphonates; Doxorubicin; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Renal Dialysis; Treatment Outcome; Vincristine; Zoledronic Acid | 2009 |
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Osteolysis; Pamidronate; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Cohort Studies; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Incidence; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Risk; Treatment Outcome; Zoledronic Acid | 2011 |
Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.
Topics: Adult; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Male; Pain; Radiography; Treatment Outcome; Young Adult; Zoledronic Acid | 2011 |
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Comorbidity; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2011 |
Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.
Topics: Adult; Aged; Bone Diseases; Bone Resorption; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pain Measurement; Positron-Emission Tomography; Quality of Life; Retrospective Studies; Spine; Treatment Outcome; Zoledronic Acid | 2012 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Neoplasms; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2012 |
Use of zoledronate for treatment of a bone fragility disorder in horses.
Topics: Animals; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Horse Diseases; Horses; Imidazoles; Male; Prospective Studies; Radionuclide Imaging; Treatment Outcome; Zoledronic Acid | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cancer Care Facilities; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Middle Aged; Pamidronate; Registries; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2013 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Progression; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Cell Cycle; Combined Modality Therapy; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Orthopedics; Radiopharmaceuticals; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Zoledronic Acid | 2008 |